SGLT2 inhibitors for diabetes are linked to increased risk of lower limb amputation

Patients with type 2 diabetes treated with sodium glucose cotransporter 2 (SGLT2) inhibitors have a higher risk of lower limb amputation and diabetic ketoacidosis than those who take glucagon-like peptide 1 (GLP1) receptor agonists, a study published in The BMJ has found.1

SGLT2 inhibitors are increasingly used in treating type 2 diabetes. But some studies suggest that they are associated with serious complications, including lower limb amputation, bone fracture, diabetic ketoacidosis, acute kidney injury, serious urinary tract infections, venous thromboembolism, and acute pancreatitis.

To better understand these …